Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PSTX

Poseida Therapeutics (PSTX) Stock Price, News & Analysis

Poseida Therapeutics logo

About Poseida Therapeutics Stock (NASDAQ:PSTX)

Advanced Chart

Key Stats

Today's Range
$9.50
$9.50
50-Day Range
$9.33
$9.60
52-Week Range
$2.32
$9.67
Volume
N/A
Average Volume
1.06 million shs
Market Capitalization
$928.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50
Consensus Rating
Hold

Company Overview

Poseida Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

PSTX MarketRank™: 

Poseida Therapeutics scored higher than 10% of companies evaluated by MarketBeat, and ranked 890th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Poseida Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Poseida Therapeutics has received no research coverage in the past 90 days.

  • Read more about Poseida Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Poseida Therapeutics are expected to decrease in the coming year, from ($1.02) to ($1.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Poseida Therapeutics is -15.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Poseida Therapeutics is -15.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Poseida Therapeutics has a P/B Ratio of 8.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for PSTX.
  • Dividend Yield

    Poseida Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Poseida Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for PSTX.
  • Search Interest

    1 people have searched for PSTX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Poseida Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.90% of the stock of Poseida Therapeutics is held by insiders.

  • Percentage Held by Institutions

    46.87% of the stock of Poseida Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Poseida Therapeutics' insider trading history.
Receive PSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PSTX Stock News Headlines

Roche set to finalise $1.5bn Poseida Therapeutics takeover
Here's the last trade you should make before heading out for the weekend tomorrow.
Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.
Poseida Therapeutics downgraded to Neutral from Overweight at Piper Sandler
See More Headlines

PSTX Stock Analysis - Frequently Asked Questions

Poseida Therapeutics, Inc. (NASDAQ:PSTX) released its quarterly earnings results on Thursday, November, 7th. The company reported $0.21 earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.63. The company had revenue of $71.75 million for the quarter, compared to analysts' expectations of $15 million. Poseida Therapeutics had a negative trailing twelve-month return on equity of 72.26% and a negative net margin of 40.28%.

Poseida Therapeutics (PSTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Poseida Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Broadcom (AVGO).

Company Calendar

Last Earnings
11/07/2024
Today
7/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PSTX
Fax
N/A
Employees
260
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.50
High Stock Price Target
$10.00
Low Stock Price Target
$9.00
Potential Upside/Downside
0.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$123.43 million
Pretax Margin
-40.25%

Debt

Sales & Book Value

Annual Sales
$150.86 million
Price / Cash Flow
N/A
Book Value
$1.08 per share
Price / Book
8.80

Miscellaneous

Free Float
94,939,000
Market Cap
$928.85 million
Optionable
Optionable
Beta
1.63
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:PSTX) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners